European Spine Journal

, Volume 22, Issue 9, pp 1921–1935 | Cite as

A systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciatica

  • Nefyn H. Williams
  • Ruth Lewis
  • Nafees Ud Din
  • Hosam E. Matar
  • Deborah Fitzsimmons
  • Ceri J. Phillips
  • Alex Sutton
  • Kim Burton
  • Maggie Hendry
  • Sadia Nafees
  • Clare Wilkinson
Review Article

Abstract

Purpose

Systematic review comparing biological agents, targeting tumour necrosis factor α, for sciatica with placebo and alternative interventions.

Methods

We searched 21 electronic databases and bibliographies of included studies. We included randomised controlled trials (RCTs), non-RCTs and controlled observational studies of adults who had sciatica treated by biological agents compared with placebo or alternative interventions.

Results

We pooled the results of six studies (five RCTs and one non-RCT) in meta-analyses. Compared with placebo biological agents had: better global effects in the short-term odds ratio (OR) 2.0 (95 % CI 0.7–6.0), medium-term OR 2.7 (95 % CI 1.0–7.1) and long-term OR 2.3 [95 % CI 0.5 to 9.7); improved leg pain intensity in the short-term weighted mean difference (WMD) −13.6 (95 % CI −26.8 to −0.4), medium-term WMD −7.0 (95 % CI −15.4 to 1.5), but not long-term WMD 0.2 (95 % CI −20.3 to 20.8); improved Oswestry Disability Index (ODI) in the short-term WMD −5.2 (95 % CI −14.1 to 3.7), medium-term WMD −8.2 (95 % CI −14.4 to −2.0), and long-term WMD −5.0 (95 % CI −11.8 to 1.8). There was heterogeneity in the leg pain intensity and ODI results and improvements were no longer statistically significant when studies were restricted to RCTs. There was a reduction in the need for discectomy, which was not statistically significant, and no difference in the number of adverse effects.

Conclusions

There was insufficient evidence to recommend these agents when treating sciatica, but sufficient evidence to suggest that larger RCTs are needed.

Keywords

Sciatica Systematic review Meta-analysis Biological agents Tumour necrosis factor α 

Supplementary material

586_2013_2739_MOESM1_ESM.bmp (1.3 mb)
Supplementary material 1 (BMP 1332 kb)
586_2013_2739_MOESM2_ESM.bmp (1.4 mb)
Supplementary material 2 (BMP 1415 kb)
586_2013_2739_MOESM3_ESM.bmp (749 kb)
Supplementary material 3 (BMP 748 kb)
586_2013_2739_MOESM4_ESM.bmp (1.4 mb)
Supplementary material 4 (BMP 1417 kb)
586_2013_2739_MOESM5_ESM.bmp (749 kb)
Supplementary material 5 (BMP 748 kb)
586_2013_2739_MOESM6_ESM.bmp (334 kb)
Supplementary material 6 (BMP 334 kb)
586_2013_2739_MOESM7_ESM.doc (64 kb)
Supplementary material 7 (DOC 63 kb)

References

  1. 1.
    Deyo RA, Rainville J, Kent DL (1992) What can the history and physical examination tell us about low back pain? J Amer Med Assoc 268:760–765CrossRefGoogle Scholar
  2. 2.
    Weber H, Holme I, Amlie E (1993) The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine 18:1433–1438PubMedGoogle Scholar
  3. 3.
    Mixer WJ, Barr JS (1934) Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med 211:210–215CrossRefGoogle Scholar
  4. 4.
    Goupille P, Jayson MI, Valat JP, Freemont AJ (1998) The role of inflammation in disc herniation-associated radiculopathy. Semin Arthritis Rheum 28:60–71PubMedCrossRefGoogle Scholar
  5. 5.
    Konstantinou K, Dunn KM (2008) Sciatica: review of epidemiological studies and prevalence estimates. Spine 33:2464–2472PubMedCrossRefGoogle Scholar
  6. 6.
    Bush K, Cowan N, Katz DE, Gishen P (1992) The natural history of sciatica associated with disc pathology; a prospective study with clinical and independent radiological follow-up. Spine 18:1433–1438Google Scholar
  7. 7.
    Tubach F, Beaute J, Leclerc A (2004) Natural history and prognostic indicators of sciatica. J Clin Epidemiol 57:174–179PubMedCrossRefGoogle Scholar
  8. 8.
    Weber H, Holme I, Amlie E (1993) The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine 18:1433–1438PubMedGoogle Scholar
  9. 9.
    van Tulder MW, Koes BW, Bouter LM (1995) A cost of illness study of back pain in the Netherlands. Pain 62:233–240PubMedCrossRefGoogle Scholar
  10. 10.
    The NHS Information Centre, Hospital Episode Statistics for England, Inpatient statistics, Total procedures and interventions 2010–11. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=210. Accessed 23 August 2012
  11. 11.
    Cooper RG, Freemont AJ (2004) TNF-α blockade for herniated intervertebral disc-induced sciatica: a way forward at last? Rheum 43:119–121CrossRefGoogle Scholar
  12. 12.
    Lewis R, Williams NH, Matar HE, Din N, Fitzsimmons D, Phillips C, Jones M, Sutton A, Burton K, Nafees S, Hendry M, Rickard I, Chakraverty R, Wilkinson C (2011) The clinical effectiveness and cost effectiveness of management strategies for sciatica: systematic review and economic model. Health Technol Assess 15(39):353–467Google Scholar
  13. 13.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) The PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedCrossRefGoogle Scholar
  14. 14.
    van Tulder MW, Furlan A, Bombardier C, Bouter L (2003) Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane collaboration back review group. Spine 28:1290–1299PubMedGoogle Scholar
  15. 15.
    Effective Public Health Practice Project (2010) Quality assessment tool for quantitative studies. http://www.ephpp.ca/PDF/Quality%20Assessment%20Tool_2010_2.pdf. Accessed 23 August 2012
  16. 16.
    Higgins JPT, Deeks JJ (2008) Selecting studies and collecting data. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester (UK), pp 151–185CrossRefGoogle Scholar
  17. 17.
    Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59:7–10PubMedCrossRefGoogle Scholar
  18. 18.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  19. 19.
    Becker C, Heidersdorf S, Drewlo S, de Rodriguez SZ, Kramer J, Willburger RE (2007) Efficacy of epidural injections with autologous conditioned serum for lumbar radicular compression. Spine 32:1803–1808PubMedCrossRefGoogle Scholar
  20. 20.
    Cohen SP, Bogduk N, Dragovich A, Buckemaier CC III, Griffith S, Kurihara C, Raymond JL, Richter PJ, Williams N, Yaksh TL (2009) Randomized, double-blind, placebo-controlled, dose-response and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology 110:1116–1126PubMedCrossRefGoogle Scholar
  21. 21.
    Genevay S, Viatte S, Finckh A, Zufferey P, Balague F, Gabay C (2010) Adalimumab in severe and acute sciatica; a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:2339–2346PubMedCrossRefGoogle Scholar
  22. 22.
    Karppinen J, Korhonen T, Hammond A, Bowman C, Malmivaara A, Veeger N, Seitsalo S, Hurri H (2009) The efficacy of infliximab in sciatica induced by disc herniations located at L3/4 or L4/5: a small-scale randomized controlled trial. Open Spine J 1:9–13CrossRefGoogle Scholar
  23. 23.
    Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren K-A, Jarvinen S, Niirimaki J, Veeger N, Seitsalo S, Hurri H (2005) The treatment of disc herniation induced sciatica with infliximab; results of a randomized, controlled 3 month follow-up study. Spine 30:2724–2728PubMedCrossRefGoogle Scholar
  24. 24.
    Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren K-A, Bowman C, Hammond A, Kirkham B, Jarvinen S, Niirimaki J, Veeger N, Haapea M, Torkki M, Tervonen O, Seitsalo S, Hurri H (2006) The treatment of disc herniation induced sciatica with infliximab; one year follow-up results of FIRST II, a randomised controlled trial. Spine 31:2759–2766PubMedCrossRefGoogle Scholar
  25. 25.
    Okoro T, Tafazal SI, Longworth S, Sell PJ (2010) Tumour necrosis factor α-blocking agent (etanercept); a triple blind randomized controlled trial of its use in treatment of sciatica. J Spinal Disord Tech 23:74–77PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen SP, White RL, Kurihara C, Larkin TM, Chang A, Griffith SR, Gilligan C, Larkin R, Morlando B, Pasquina PF, Yaksh TL, Nguyen C (2012) Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter randomized trial. Ann Intern Med 156:551–559PubMedCrossRefGoogle Scholar
  27. 27.
    Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren K-A, Rantanen P, Tervonen O, Niinimaki J, Seitsalo S, Hurri H (2003) Tumour necrosis factor-α monoclonal antibody, infliximab, used to manage severe sciatica. Spine 28:750–754PubMedGoogle Scholar
  28. 28.
    Korhonen T, Karppinen J, Malmivaara A, Autio R, Niinimaki J, Paimela L, Kyllonen E, Lindgren K-A, Tervonen O, Seitsalo S, Hurri H (2004) Efficacy of infliximab for disc herniation induced sciatica; one year follow-up. Spine 29:2115–2119PubMedCrossRefGoogle Scholar
  29. 29.
    Genevay S, Stingelin S, Gabay C (2004) Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis 63:1120–1123PubMedCrossRefGoogle Scholar
  30. 30.
    Turner RM, Spiegelhalter DJ, Smith GCS, Thompson SG (2009) Bias modelling in evidence synthesis. J R Stat Soc Ser A Stat Soc 172:21–47PubMedCrossRefGoogle Scholar
  31. 31.
    Eddy DM, Hasselblad V, Shachter R (1990) An introduction to Bayesian methods for meta-analysis: the confidence profile method. Med Decis Making 10:15–23PubMedCrossRefGoogle Scholar
  32. 32.
    Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27):1–91Google Scholar
  33. 33.
    Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59:342–353PubMedCrossRefGoogle Scholar
  34. 34.
    Balshema H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401–406CrossRefGoogle Scholar
  35. 35.
    Burgher AM, Hoelzer BC, Schroeder DR, Wilson GA, Huntoon MA (2011) Transforaminal epidural clonidine versus corticosteroid for acute lumbosacral radiculopathy due to intervertebral disc herniation. Spine 36:E293–E300PubMedGoogle Scholar
  36. 36.
    Milligan ED, Sloane EM, Langer SJ, Hughes TS, Jekich BM, Frank MG, Mahoney JH, Levkoff LH, Maier SF, Cruz PE, Flotte TR, Johnson KW, Mahoney MM, Chavez RA, Leinwand LA, Watkins LR (2006) Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain 126(1–3):294–308PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Nefyn H. Williams
    • 1
    • 2
  • Ruth Lewis
    • 1
  • Nafees Ud Din
    • 1
  • Hosam E. Matar
    • 3
  • Deborah Fitzsimmons
    • 4
  • Ceri J. Phillips
    • 4
  • Alex Sutton
    • 5
  • Kim Burton
    • 6
  • Maggie Hendry
    • 1
  • Sadia Nafees
    • 1
  • Clare Wilkinson
    • 1
  1. 1.North Wales Centre for Primary Care Research, North Wales Clinical SchoolBangor UniversityWrexhamUK
  2. 2.North Wales Organisation for Randomised Trials in Health (NWORTH)Bangor UniversityBangorUK
  3. 3.Sheffield Teaching HospitalsSheffieldUK
  4. 4.College of Human and Health SciencesSwansea UniversitySwanseaUK
  5. 5.Department of Health SciencesUniversity of LeicesterLeicesterUK
  6. 6.Spinal Research InstituteUniversity of HuddersfieldHuddersfieldUK

Personalised recommendations